新型口服抗凝药物的药动学特性及其临床应用案例

近年来，新型口服抗凝药物成为治疗血栓栓塞性疾病的主要抗凝方案，较维生素K拮抗剂，其具有较高的抗凝效果，使抗凝抗栓方法获得较多新选择。目前，新型口服抗凝药物种类较多、半衰期短，不同药物之间的药物作用不同，治疗效果也不同。因此，本文对希美加群（已撤市）、达比加群酯、利伐沙班、阿哌沙班的药动力学进行分析，并对不同抗凝药物临床应用现状进行阐明，以此在最大程度上保障新型口服抗凝药物在临床实践中的应用合理性。

Pharmacokinetic properties of new oral anticoagulants and their clinicalapplication cases

In recent years, new oral anticoagulant drugshave become the main anticoagulation regimens in the treatment ofthromboembolic diseases. Compared with vitamin K antagonists, they have higheranticoagulant effects, so that more new options for anticoagulation andantithrombotic methods have been obtained. At present, there are many types ofnew oral anticoagulant drugs with a short half-life, different drug effects,and different therapeutic effects. Therefore, this paper analyzes thepharmacokinetics of ximegatran (withdrawn from the market), dabigatranetexilate, rivaroxaban, and apixaban and clarifies the clinical applicationstatus of different anticoagulant drugs, so as to ensure the rationality of theapplication of new oral anticoagulant drugs in clinical practice.